Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparin

Anaesthesia

Volumn 62, Issue 11, 2007, Pages 1175-1178

  Simons, R ^a   Mallett, S V ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMIODARONE; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; BECLOMETASONE; BENDROFLUMETHIAZIDE; BILIRUBIN; CREATININE; ENALAPRIL; ENOXAPARIN; FIBRINOGEN; HEMOGLOBIN; HEPARIN LYASE; SALBUTAMOL; SALMETEROL; WARFARIN;

AGED; ANAMNESIS; BILE DUCT CARCINOMA; BILE DUCT RECONSTRUCTION; CASE REPORT; CONFERENCE PAPER; DOSE RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPIDURAL ANESTHESIA; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; LABORATORY TEST; MALE; OBSTRUCTIVE JAUNDICE; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; THROMBOELASTOGRAPHY;

AGED; ANESTHESIA, EPIDURAL; ANTICOAGULANTS; BLOOD COAGULATION; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; RENAL INSUFFICIENCY; THROMBELASTOGRAPHY;

EID: 35048890556     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2007.05225.x     Document Type: Conference Paper

References (21)

1. Hynson J, Katz J, Bueff H. Epidural haematoma associated with enoxaparin. Anesthesia and Analgesia 1996 82:1072 5.
2. Weitz J. Low molecular weight heparins. New England Journal of Medicine 1997 337:688 98.
3. Horlocker T, Wedel D, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks. (The Second Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Regional Anesthesia and Pain Medicine 2003 28:172 97.
4. Hisch J, Raschke R. Heparin and low-molecular weight heparin. The Seventh ACPP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126:S188 203.
5. Sanderink G, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of prophylactic dose of enoxaparin once daily over four days in patients with renal impairment. Thrombosis Research 2002 105:225 31.
6. Bastani B, Gonzales E. Prolonged anti-factor Xa levels in a patient with moderate renal insufficiency receiving enoxaparin. American Journal of Nephrology 2002 22:403 14.
7. Brophy DF, Wazny LD, Gehr TWB, Comstock TJ, Venitz J. The pharmacokinetics of subcutaneous enoxaparin in end stage renal disease. Pharmacotherapy 2001 21:169 74.
8. Walenga J. Practical issues on the laboratory monitoring of low molecular weight heparins and related polysaccharides. Seminars in Thrombosis and Haemostasis 1993 19:69 72.
9. Horlocker TT, Wedel DJ. Neuraxial block and low molecular weight heparin: balancing perioperative analgesia and thromboprophylaxis. Regional Anesthesia and Pain Medicine 1998 23 (Suppl. 2 164 77.
10. Coppell JA, Thalheimer U, Zambruni A, et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagulation and Fibinrolysis 2006 17:97 104.
11. Zmunda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low molecular weight heparin and heparinoid on thromboelastographic assay of blood coagulation. American Journal of Clinical Pathology 2000 113:725 31.
12. Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thrombosis and Haemostasis 2004 92:1296 302.
13. Klien SM, Slaughter TF, Vail PT, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesthesia and Analgesia 2000 91:1091 5.
14. Cheney FW, Domino KB, Caplan RA, Posener K. Nerve injury associated with anesthesia. A closed claims analysis. Anesthesiology 1999 90:1062 9.
15. Buckley M, Sorkin E. Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992 44:465 97.
16. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimes and guidelines for regional anesthetic management. Anesthesia and Analgesia 1997 85:874 85.
17. Al Dieri R, Alban S, Beguin S, Hemker C. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. Journal of Thrombosis and Haemostasis 2006 4:83 9.
18. Becker RC, Spencer FA, Gibson M, Rush JE. Influence of patient characteristics and renal function on factor Xa inhibition, pharmacokinetics and pharmacodynamics after enoxaparin administration in non ST-segment elevation acute coronary syndromes. American Heart Journal 2002 143:753 9.
19. Carroll RC, Craft RM, Whitaker GL, Snider CC. Thromboelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients. Thrombosis Research 2006 (E-publication ahead of print [accessed 16 February 2007].
20. Brophy DF, Carr ME, Martin EJ, Venitz J, Gehr TWB. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. American Journal of Kidney Disease 2004 44:270 7.
21. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thrombosis and Haemostasis 1989 62:940 4.